⌘+K

Pulse Explore Clubs Researchers Journals

Home Clubs Explore

May 31, 2024Journal of Infection and Public HealthOpen Access

The effect of oral antiviral therapy for COVID-19 in managing non-hospitalized patients with lung cancer

Wan‐Hsuan Hsu Bo-Wen Shiau Ya‐Wen Tsai Jheng‐Yan Wu Po‐Yu Huang Min‐Hsiang Chuang Tinghui Liu Chih‐Cheng Lai Tzu-Chieh Weng

View Full Paper

Ask AI

Bookmark

Share

Abstract

The effectiveness of oral antiviral therapy including nirmatrelvir plus ritonavir and molnupiravir in managing COVID-19 among individuals with pre-existing lung cancer was unclear. Therefore, this study was conducted to evaluate the usefulness of antiviral agents in the management of COVID-19 among patients with lung cancer.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Hsu et al. (2024) studied this question.

synapsesocial.com/papers/68e6784fb6db64358760231b https://doi.org/10.1016/j.jiph.2024.05.053

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Effectiveness of recently-approved oral antiviral medications on the outcome of patients with mild-to-moderate COVID-19 and pre–existing chronic obstructive pulmonary diseases2024 · 2 citations
2Comparing Molnupiravir to Nirmatrelvir/Ritonavir (Paxlovid) in the Treatment of Mild-to-Moderate COVID-19 in Immunocompromised Cancer Patients2024 · 9 citations
3The effectiveness of oral anti-SARS-CoV-2 agents in non-hospitalized COVID-19 patients with nonalcoholic fatty liver disease: a retrospective study2024 · 6 citations
4Clinical effectiveness of oral antiviral agents for treating non-hospitalized COVID-19 patients with chronic kidney disease2024 · 3 citations
5Effectiveness of oral antivirals in reducing adverse outcomes in asthmatic patients with non-severe COVID-19: A multi-institutional retrospective cohort studyCohort Study · 2026